Lepodisiran
Highest phase reached
Phase 2
Drug type
Oligonucleotide
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Oligonucleotide
- Drug name
- Lepodisiran
- duplex of all p ambo 4 de hydroxymethyl 4 hydroxymethylphosphinoyl methoxy 2 o methylthiouridylyl 2 deoxy 2 fluorothioadenylyl 3 5 2 deoxy 2 fluorothioguanylyl 3 5 2 deoxy 2 fluoroadenylyl 3 5 2 deoxy 2 fluorouridylyl 3 5 2 o methylguanylyl 3 5 2 deoxy 2 fluoroadenylyl 3 5 2 o methylcytidylyl 3 5 2 o methylcytidylyl 3 5 2 deoxy 2 fluoroadenylyl 3 5 2 o methyladenylyl 3 5 2 o methylguanylyl 3 5 2 o methylcytidylyl 3 5 2 deoxy 2 fluorouridylyl 3 5 2 o methyluridylyl 3 5 2 o methylguanylyl 3 5 2 o methylguanylyl 3 5 2 o methylcytidylyl 3 5 2 o methyladenylyl 3 5 2 o methylthioadenylyl 3 5 2 o methylthioguanylyl 3 5 2 o methylguanosine and all p ambo 2 o methylthiouridylyl 5 3 2 o methyluridylyl 5 3 2 o methylguanylyl 5 3 2 o methylcytidylyl 5 3 2 o methylcytidylyl 5 3 2 o methyladenylyl 5 3 2 o methyladenylyl 5 3 2 deoxy 2 fluoroguanylyl 5 3 2 deoxy 2 fluorocytidylyl 5 3 2 deoxy 2 fluorouridylyl 5 3 2 deoxy 2 fluorouridylyl 5 3 2 o methylguanylyl 5 3 2 o methylguanylyl 5 3 2 o methyluridylyl 5 3 2 o methylcytidylyl 5 3 2 o methyladenylyl 5 3 2 o methyluridylyl 5 3 2 o methylcytidylyl 5 3 2 o methyluridylyl 5 3 2 o methyladenylyl 5 3 2 o methylguanylyl 5 3 2 o methylcytidylyl 5 3 2 o methyladenylyl 5 3 2 o methylguanylyl 5 3 2 o methylcytidylyl 5 3 2 o methylcytidylyl 5 3 2 o methylguanylyl 5 3 2 2 5 2 acetamido 2 deoxy b d galactopyranosyl oxy pentanamido ethoxy ethoxy methyl adenylyl 5 3 2 2 5 2 acetamido 2 deoxy b d galactopyranosyl oxy pentanamido ethoxy ethoxy methyl adenylyl 5 3 2 2 5 2 acetamido 2 deoxy b d galactopyranosyl oxy pentanamido ethoxy ethoxy methyl adenylyl 5 3 2 o methylguanylyl 5 3 2 o methylguanylyl 5 3 2 o methylcytidylyl 5 3 2 o methyluridylyl 5 3 2 o methylguanylyl 5 3 2 o methylcytosine
- duplex of all-P-ambo-4′-de(hydroxymethyl)-4′-[(hydroxymethylphosphinoyl)methoxy]-2′-O-methylthiouridylyl-2′-deoxy-2′-fluorothioadenylyl-(3'→5')-2′-deoxy-2′-fluorothioguanylyl-(3'→5')-2′-deoxy-2′-fluoroadenylyl-(3'→5')-2′-deoxy-2′-fluorouridylyl-(3'→5')-2′-O-methylguanylyl-(3'→5')-2′-deoxy-2′-fluoroadenylyl-(3'→5')-2′-O-methylcytidylyl-(3'→5')-2′-O-methylcytidylyl-(3'→5')-2′-deoxy-2′-fluoroadenylyl-(3'→5')-2′-O-methyladenylyl-(3'→5')-2′-O-methylguanylyl-(3'→5')-2′-O-methylcytidylyl-(3'→5')-2′-deoxy-2′-fluorouridylyl-(3'→5')-2′-O-methyluridylyl-(3'→5')-2′-O-methylguanylyl-(3'→5')-2′-O-methylguanylyl-(3'→5')-2′-O-methylcytidylyl-(3'→5')-2′-O-methyladenylyl-(3'→5')-2′-O-methylthioadenylyl-(3'→5')-2′-O-methylthioguanylyl-(3'→5')-2′-O-methylguanosine and all-P-ambo-2′-O-methylthiouridylyl-(5′→3′)-2′-O-methyluridylyl-(5′→3′)-2′-O-methylguanylyl-(5′→3′)-2′-O-methylcytidylyl-(5′→3′)-2′-O-methylcytidylyl-(5′→3′)-2′-O-methyladenylyl-(5′→3′)-2′-O-methyladenylyl-(5′→3′)-2′-deoxy-2′-fluoroguanylyl-(5′→3′)-2′-deoxy-2′-fluorocytidylyl-(5′→3′)-2′-deoxy-2′-fluorouridylyl-(5′→3′)-2′-deoxy-2′-fluorouridylyl-(5′→3′)-2′-O-methylguanylyl-(5′→3′)-2′-O-methylguanylyl-(5′→3′)-2′-O-methyluridylyl-(5′→3′)-2′-O-methylcytidylyl-(5′→3′)-2′-O-methyladenylyl-(5′→3′)-2′-O-methyluridylyl-(5′→3′)-2′-O-methylcytidylyl-(5′→3′)-2′-O-methyluridylyl-(5′→3′)-2′-O-methyladenylyl-(5′→3′)-2′-O-methylguanylyl-(5′→3′)-2′-O-methylcytidylyl-(5′→3′)-2′-O-methyladenylyl-(5′→3′)-2′-O-methylguanylyl-(5′→3′)-2′-O-methylcytidylyl-(5′→3′)-2′-O-methylcytidylyl-(5′→3′)-2′-O-methylguanylyl-(5′→3′)-{2-[2-{5-[(2-acetamido-2-deoxy-b-D-galactopyranosyl)oxy]pentanamido}ethoxy)ethoxy]methyl}adenylyl-(5′→3′)-{2-[2-{5-[(2-acetamido-2-deoxy-b-D-galactopyranosyl)oxy]pentanamido}ethoxy)ethoxy]methyl}adenylyl-(5′→3′)-{2-[2-{5-[(2-acetamido-2-deoxy-b-D-galactopyranosyl)oxy]pentanamido}ethoxy)ethoxy]methyl}adenylyl-(5′→3′)-2′-O-methylguanylyl-(5′→3′)-2′-O-methylguanylyl-(5′→3′)-2′-O-methylcytidylyl-(5′→3′)-2′-O-methyluridylyl-(5′→3′)-2′-O-methylguanylyl-(5′→3′)-2′-O-methylcytosine
- lepodisiran
- Lepodisiran
- lepodisiran [INN]
- LEPODISIRAN [USAN]
- Lepodisiran [WHO-DD]
- lepodisiran inn
- lepodisiran usan
- lepodisiran who dd
- ly 3819469 free acid
- LY-3819469 FREE ACID
- ly3819469
- LY3819469
- ly3819469 free acid
- LY3819469 FREE ACID
- rna 4 de hydroxymethyl 4 hydroxymethoxyphosphinyl methoxy um sp 2 deoxy 2 fluoro a sp 2 deoxy 2 fluoro g sp 2 deoxy 2 fluoro a 2 deoxy 2 fluoro u gm 2 deoxy 2 fluoro a cm cm 2 deoxy 2 fluoro a am gm cm 2 deoxy 2 fluoro u um gm gm cm am am sp gm sp gm complex with rna um sp um gm cm cm am am 2 deoxy 2 fluoro g 2 deoxy 2 fluoro c 2 deoxy 2 fluoro u 2 deoxy 2 fluoro u gm gm um cm am um cm um am gm cm am gm cm cm gm 2 o 2 2 5 2 acetylamino 2 deoxy β d galactopyranosyl oxy 1 oxopentyl amino ethoxy ethoxy methyl a 2 o 2 2 5 2 acetylamino 2 deoxy β d galactopyranosyl oxy 1 oxopentyl amino ethoxy ethoxy methyl a 2 o 2 2 5 2 acetylamino 2 deoxy β d galactopyranosyl oxy 1 oxopentyl amino ethoxy ethoxy methyl a gm gm cm um gm cm 1 1
- RNA, ([4′-de(hydroxymethyl)-4′-[(hydroxymethoxyphosphinyl)methoxy]]Um-sp-(2′-deoxy-2′-fluoro)A-sp-(2′-deoxy-2′-fluoro)G-sp-(2′-deoxy-2′-fluoro)A-(2′-deoxy-2′-fluoro)U-Gm-(2′-deoxy-2′-fluoro)A-Cm-Cm-(2′-deoxy-2′-fluoro)A-Am-Gm-Cm-(2′-deoxy-2′-fluoro)U-Um-Gm-Gm-Cm-Am-Am-sp-Gm-sp-Gm), complex with RNA (Um-sp-Um-Gm-Cm-Cm-Am-Am-(2′-deoxy-2′-fluoro)G-(2′-deoxy-2′-fluoro)C-(2′-deoxy-2′-fluoro)U-(2′-deoxy-2′-fluoro)U-Gm-Gm-Um-Cm-Am-Um-Cm-Um-Am-Gm-Cm-Am-Gm-Cm-Cm-Gm-[2′-O-[[2-[2-[[5-[[2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]-1-oxopentyl]amino]ethoxy]ethoxy]methyl]]A-[2′-O-[[2-[2-[[5-[[2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]-1-oxopentyl]amino]ethoxy]ethoxy]methyl]]A-[2′-O-[[2-[2-[[5-[[2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]-1-oxopentyl]amino]ethoxy]ethoxy]methyl]]A-Gm-Gm-Cm-Um-Gm-Cm) (1:1)
- CAS registry numbers
- 2808361-18-2
- ChEMBL ID
- CHEMBL6068445
- FDA ingredient codes (UNII)
- X4BE7S8PN9
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- lepodisiran
- Type
- Nucleic acid
Investigated indications
- Condition
- Cardiovascular Diseases
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000319
- Subject identifier
- D002318
- Condition identifier
- EFO_0000319
- Condition identifier
- EFO_0001421
- Highest recorded phase
- 1
- Condition identifier
- HP_0000083
- Highest recorded phase
- 1
- Condition identifier
- HP_0001410
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0004995
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
Sequences
- Component
- Sequence
- Type
- Nucleic Acid
- Sequence
- (5'-3') U=U-G-C-A-A-G-C-U-U-G-G-U-C-A-U-C-U-A-G-C-A-G-C-C-G (3'-5') G=G=A-A-C-G-U-U-C-G-A-A-C-C-A-G-U-A=G=A=U-C-G-U-C-G-G
Related records
Trials (6)
- A Study of Lepodisiran (LY3819469) in Participants With Normal, Mild, Moderate, or Severe Liver Function
- A Study of LY3819469 in Healthy Participants
- A Study of LY3819469 in Participants With Elevated Lipoprotein(a) [Lp(a)]
- A Study of LY3819469 in Participants With Impaired and Normal Renal Function
- A Study to Compare Two Formulations of LY3819469 in Healthy Participants
- A Study to See if Lepodisiran Can Reduce Plaque in Coronary Arteries of Adults With Elevated Lp(a) Who Have Had Heart Events or Are at High Risk
In development for (2)
- Cardiovascular disorder Phase 1
- Liver disorder Phase 1